Paid Clinical Trials Oklahoma
Discover 872 paid clinical trials in Oklahoma. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
Sponsor:
Pfizer
Location:
Code:
NCT06398626
Conditions
Colitis, Ulcerative
Eligibility Criteria
Sex: All
Age: 18 - 64
Healthy Volunteers: Not accepted
Interventions
Etrasimod
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Sponsor:
GB002, Inc.
Location:
Code:
NCT05934526
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Seralutinib
Generic Dry Powder Inhaler
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Sponsor:
Target PharmaSolutions, Inc.
Location:
Code:
NCT03661866
Conditions
Atopic Dermatitis
Alopecia Areata
Hidradenitis Suppurativa
Vitiligo
Psoriasis
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
A Study of NX-1607 in Adults With Advanced Malignancies
Sponsor:
Nurix Therapeutics, Inc.
Location:
Code:
NCT05107674
Conditions
Ovarian Cancer, Epithelial
Gastric Cancer
GastroEsophageal Junction (GEJ) Cancer
Head and Neck Squamous Cell Carcinoma
Metastatic or Unresectable Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
NX-1607
Paclitaxel
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06393374
Conditions
Triple-Negative Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
sac-TMT
Capecitabine
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05111574
Conditions
Anal Melanoma
Bladder Melanoma
Cervical Melanoma
Esophageal Melanoma
Gallbladder Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
Sponsor:
CinPhloro Pharma, LLC
Location:
Code:
NCT06153420
Conditions
Irritable Bowel Syndrome With Diarrhea
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CIN-103
Placebo
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Sponsor:
Immunocore Ltd
Location:
Code:
NCT04262466
Conditions
Select Advanced Solid Tumors
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Brenetafusp
Brenetafusp and pembrolizumab
Brenetafusp and chemotherapy
Brenetafusp and monoclonal antibodies and chemotherapy
Brenetafusp and tebentafusp